BACKGROUND: Chronic HIV-1 infection is associated with excessive immune activation and immune exhaustion. We investigated the relationship of these 2 phenotypes and frequency of regulatory T cells (Tregs) in controlled and uncontrolled chronic HIV-1 infection. METHODS: Immune exhaustion marker PD-1, its ligand PD-L1, CD4CD25 FoxP3 Tregs, HLA-DR, and CD38 coexpression as activation markers were investigated in peripheral blood lymphocytes of 44 HIV-1-infected patients and 11 HIV-1-uninfected controls by multicolor flow cytometry. RESULTS: Activated and PD-1 expressing T cells were increased, and Tregs were decreased in HIV-1-infected patients as compared with controls, and alterations were greatest in viremic patients. The proportion of activated CD8 T cells exceeded activated CD4 T cells. Tregs had an inverse correlation with activated T cells and PD-1 expressing T cells. PD-L1 was highly expressed on monocytes and to a lesser extent on T lymphocytes of patients. These abnormalities partially reversed with virologic control after potent antiretroviral therapy. CONCLUSIONS: Immune exhaustion is a component of aberrant immune activation in chronic HIV-1 infection and is associated with loss of Tregs and ongoing virus replication. These defects are corrected partially with effective virologic control by potent antiretroviral therapy.
BACKGROUND: Chronic HIV-1 infection is associated with excessive immune activation and immune exhaustion. We investigated the relationship of these 2 phenotypes and frequency of regulatory T cells (Tregs) in controlled and uncontrolled chronic HIV-1 infection. METHODS: Immune exhaustion marker PD-1, its ligand PD-L1, CD4CD25FoxP3 Tregs, HLA-DR, and CD38 coexpression as activation markers were investigated in peripheral blood lymphocytes of 44 HIV-1-infectedpatients and 11 HIV-1-uninfected controls by multicolor flow cytometry. RESULTS: Activated and PD-1 expressing T cells were increased, and Tregs were decreased in HIV-1-infectedpatients as compared with controls, and alterations were greatest in viremic patients. The proportion of activated CD8 T cells exceeded activated CD4 T cells. Tregs had an inverse correlation with activated T cells and PD-1 expressing T cells. PD-L1 was highly expressed on monocytes and to a lesser extent on T lymphocytes of patients. These abnormalities partially reversed with virologic control after potent antiretroviral therapy. CONCLUSIONS: Immune exhaustion is a component of aberrant immune activation in chronic HIV-1 infection and is associated with loss of Tregs and ongoing virus replication. These defects are corrected partially with effective virologic control by potent antiretroviral therapy.
Authors: Spencer C Liang; Yvette E Latchman; Janet E Buhlmann; Michal F Tomczak; Bruce H Horwitz; Gordon J Freeman; Arlene H Sharpe Journal: Eur J Immunol Date: 2003-10 Impact factor: 5.532
Authors: Angela Meier; Aranya Bagchi; Harlyn K Sidhu; Galit Alter; Todd J Suscovich; Daniel G Kavanagh; Hendrik Streeck; Mark A Brockman; Sylvie LeGall; Judith Hellman; Marcus Altfeld Journal: AIDS Date: 2008-03-12 Impact factor: 4.177
Authors: Catherine M Card; Paul J McLaren; Charles Wachihi; Joshua Kimani; Francis A Plummer; Keith R Fowke Journal: J Infect Dis Date: 2009-05-01 Impact factor: 5.226
Authors: Constantinos Petrovas; Benjamin Chaon; David R Ambrozak; David A Price; J Joseph Melenhorst; Brenna J Hill; Christof Geldmacher; Joseph P Casazza; Pratip K Chattopadhyay; Mario Roederer; Daniel C Douek; Yvonne M Mueller; Jeffrey M Jacobson; Viraj Kulkarni; Barbara K Felber; George N Pavlakis; Peter D Katsikis; Richard A Koup Journal: J Immunol Date: 2009-06-29 Impact factor: 5.422
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: X-D Yao; R W Omange; B M Henrick; R T Lester; J Kimani; T B Ball; F A Plummer; K L Rosenthal Journal: Mucosal Immunol Date: 2013-06-26 Impact factor: 7.313
Authors: Vaiva Vezys; Pablo Penaloza-MacMaster; Daniel L Barber; Sang-Jun Ha; Bogumila Konieczny; Gordon J Freeman; Robert S Mittler; Rafi Ahmed Journal: J Immunol Date: 2011-07-08 Impact factor: 5.422
Authors: Tricia H Burdo; Margaret R Lentz; Patrick Autissier; Anitha Krishnan; Elkan Halpern; Scott Letendre; Eric S Rosenberg; Ronald J Ellis; Kenneth C Williams Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Cynthia L Gay; Ronald J Bosch; Justin Ritz; Jason M Hataye; Evgenia Aga; Randall L Tressler; Stephen W Mason; Carey K Hwang; Dennis M Grasela; Neelanjana Ray; Josh C Cyktor; John M Coffin; Edward P Acosta; Richard A Koup; John W Mellors; Joseph J Eron Journal: J Infect Dis Date: 2017-06-01 Impact factor: 5.226
Authors: Allison Ross Eckard; Julia C Rosebush; S Thera Lee; Mary Ann O'Riordan; Jakob G Habib; Julie E Daniels; Danielle Labbato; Monika Uribe-Leitz; Ann Chahroudi; Grace A McComsey Journal: Pediatr Infect Dis J Date: 2016-12 Impact factor: 2.129
Authors: J Saison; T Ferry; J Demaret; D Maucort Boulch; F Venet; T Perpoint; F Ader; V Icard; C Chidiac; G Monneret Journal: Clin Exp Immunol Date: 2014-06 Impact factor: 4.330
Authors: Julien van Grevenynghe; Rafael A Cubas; Sandrina DaFonseca; Talibah Metcalf; Cecile L Tremblay; Lydie Trautmann; Rafick-Pierre Sekaly; John Schatzle; Elias K Haddad Journal: Cytokine Growth Factor Rev Date: 2012-06-27 Impact factor: 7.638